Background and Purpose-Some rheumatic diseases are associated with stroke. Less is known about associations with stroke subtypes or stroke risk by age. We quantified the association between stroke, its subtypes, and rheumatic diseases and identified when stroke risk is greatest. Methods-Searches of EMBASE (from 1980) and MEDLINE (from inception) to end 2014 and manual search of reference lists for studies of stroke and stroke subtypes in rheumatic diseases as well as studies measuring cerebrovascular disease from magnetic resonance imaging. Results-Prior published meta-analyses and new pooled analyses of any stroke in rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, gout, and psoriasis show an excess risk of stroke over the general population with odds ratio (OR) ranging from 1.51 (95% confidence interval: 1.39-1.62) to 2.13 (1.53-2.98). New meta-analyses of stroke subtypes in rheumatoid arthritis [ischemic: OR, 1.64 (1.32-2.05); hemorrhagic: OR, 1.68 (1.11-2.53)] and systemic lupus erythematosus [ischemic: OR, 2.11 (1.66-2.67); hemorrhagic: OR, 1.82 (1.07-3.09)] show an excess risk of stroke over the general population. Stroke risk across rheumatic diseases is highest in those aged <50 years [OR, 1.79 (1.46-2.20)] and reduces relatively with ageing [>65 years: OR, 1.14 (0.94-1.38); difference P<0.007]. Inflammatory arthropathies conveyed higher stroke risk than noninflammatory diseases (OR, 1.3, 1.2-1.3). It was not possible to adjust ORs for risk factors or treatments. Conclusions-Risk of any stroke is higher in most rheumatic diseases than in the general population, particularly <50 years. Rheumatoid arthritis and systemic lupus erythematosus increase ischemic and hemorrhagic stroke risk by 60% to 100% relative to the general population. (Stroke. 2016;47:943-950. The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/
S troke is a major health problem. Overall incidence rates are falling, 1,2 but better access to medical care and improvements in secondary prevention increase survival, so stroke prevalence, and thus health-care costs, remain high. An ageing population will increase this trend.
Rheumatic diseases such as rheumatoid arthritis (RA) are an independent risk factor for stroke. 3, 4 People with these diseases die prematurely from cardiovascular disease including stroke, 5, 6 so an understanding of stroke risk among these patients is needed to reduce mortality. However, data linking rheumatic diseases with higher stroke risk are based mostly on stroke reported from large population studies, ie, a composite outcome of any stroke. Less is known about associations between rheumatic diseases (inflammatory or noninflammatory) and major stroke subtypes whose mechanisms differ, eg, ischemic versus hemorrhagic stroke, or large artery atheromatous versus intrinsic small vessel ischemic stroke, or with conditions associated with cerebral small vessel disease (SVD), such as cognitive decline and gait disturbances. 7, 8 Population stroke incidence rises with age. Stroke early in life is rare, yet most of the stroke associated with rheumatic diseases seems to be at younger ages [9] [10] [11] [12] [13] [14] [15] and may level off, as some studies 12, 13, 16, 17 report no risk difference in those >65 years. However, there is currently no meta-analysis on the overall association of rheumatic diseases with stroke by age. Clarifying timing of greatest stroke risk has important clinical implications.
Studies to date do not fully explain the increased stroke risk among rheumatic populations by vascular risk factors. 18, 19 A proportion of stroke risk in rheumatic diseases could relate to the higher inflammatory activity seen in many arthropathies, which is systemic, nonresolving, and often only controlled with aggressive antirheumatic drugs. Inflammation, therefore, plausibly explains some of the excess risk because of atheromatous stroke as inflammation is involved in all stages of atherosclerosis from fatty streak formation to plaque disruption. [20] [21] [22] The role of inflammation in SVD is less certain, but inflammation is seen pathologically in the perforating
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April 2016 arteriolar walls and perivascular tissue. 23, 24 Endothelial damage is a primary step in atherosclerosis and SVD and factors that contribute to endothelial damage (eg, immune complex formation and complement activation) are also seen in rheumatic diseases. Our aims are to review associations between stroke and rheumatic disease, to summarize incidence rates for stroke subtypes, to calculate pooled rate ratios for stroke subtypes versus the general population, to see if risk is greatest at specific ages; and to determine if rheumatic diseases increase the risk of silent vascular disease on neuroimaging.
Methods

Study Design
We used a systematic approach to assess stroke and stroke subtypes as the outcome measure and various rheumatic diseases as the exposure. Research ethics committee approval was not required. The study was not registered in any database.
Data Sources
We prepared this review in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. 25 We used structured MeSH search terms ( 26 We categorized magnetic resonance imaging (MRI) findings according to STRIVE (Standards for Reporting Vascular Changes on Neuroimaging) guidelines. 27 We identified additional papers from reference lists and contacted authors for additional data when required.
Study Selection
We included English language studies reporting on stroke in rheumatic disease and studies that assessed brain imaging features of SVD on MRI. We excluded studies using functional MRI, positron emission tomography, single photon emission computed tomography, and Doppler ultrasound.
Data Extraction
We extracted data on study population demographics, control groups, stroke type (ischemic/hemorrhagic), ischemic stroke subtypes (large artery/lacunar), findings on stroke risk relative to a comparator group, and MRI findings. We noted if studies controlled for age and vascular risk factors.
Quality Assessment
We developed a checklist adapted from STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) 28 to assess the quality of included studies ( Table II in 
Data Synthesis and Analysis
We defined SVD from MRI features as per recent STRIVE neuroimaging standards, 27 being any of recent small subcortical infarcts, white matter hyperintensities (WMH), lacunes, microbleeds, prominent peri-vascular spaces, or atrophy. Clinically, patients might show no symptoms, or they might suffer cognitive impairment or other neurological involvement in addition to stroke (lacunar stroke accounts for ≈25% of all ischemic strokes 29 ).
We defined stroke incidence rates as number of strokes as a function of a follow-up period and stroke rate ratios as the ratio of stroke incidence rate in the observed group (eg, RA) over incidence rates in the general population. We used unadjusted (crude) rates throughout as different studies controlled for different variables making comparison of uniform adjustments impossible.
We recorded stroke incidence rates when reported and calculated them when not reported but where data (ie, number of stroke events and a follow-up period) were available. We converted all incidence rates to per 100 000 person-years. If follow-up duration (in patientyears) was not specifically reported, we estimated this by multiplying number of patients by the average years of follow-up.
Where a rheumatic disease had contributing data from >1 study, we pooled incidence rates by taking the range of available values, which did not allow us to assess heterogeneity. Next, we calculated a point estimate for incidence rate per 100 000 person-years for individual rheumatic diseases based on the weighted mean, using study size as the weighting factor and then estimated a 95% confidence interval (CI) based on the Poisson distribution as implemented in the epitools package for the statistical programming language R version 3.0.1 (http://www.r-project.org/). 30 We calculated rate ratios using the Cochrane Collaboration's Review Manager 5 software when not reported but where required data were available.
Some studies did not provided number of strokes and number of patient-years observed for the control group but instead only provided the rate ratio together with a CI. As per Cochrane Handbook, 31 CI can be converted to standard errors and the natural logarithms of rate ratios may be combined across studies using the generic inversevariance method. We used this approach to pool stroke risk for ischemic stroke and hemorrhagic stroke and for the age category pooled analysis.
We assessed between-study heterogeneity using the I 2 statistic. We used random effects models in all meta-analyses.
Results
The search returned 434 titles and abstracts; 69 papers were reviewed in full and 23 studies contributed data to new metaanalyses. We excluded studies that did not measure stroke with appropriate imaging (n=12), pathology studies (n=5), guidelines and review papers (n=4), and small studies (<50 patients) that only described imaging features of SVD (n=25) ( Figure I in the online-only Data Supplement).
Any Stroke
Prior meta-analyses and large registry studies of any stroke are reported for completeness ( Table III in Figure II in the online-only Data Supplement). We updated 2 psoriasis meta-analyses 35, 36 and added a new meta-analysis for psoriatic arthritis. The pooled odds of any stroke in psoriasis (9 studies [37] [38] [39] [40] [41] [42] [43] [44] [45] ; 6925 strokes; 400 767 patients) was 1.08 (1.00-1.16) ( Figure III RA (prototypical inflammatory rheumatic disease) showed significant risk of stroke over the general population (n=26 143 patients; OR, 1.91; 1.73-2.12) 47 whereas OA (degenerative) did not (n=40 817 patients; OR, 1.11; 0.95-1.29). 48 In direct comparison, patients with OA alone had lower stroke risk (11 633 RA versus 163 274 OA patients; OR, 1.3; 1.2-1.3, ie, higher stroke risk in RA). 49
Stroke Subtypes: Ischemic and Hemorrhagic
Incidence
Table summarizes our meta-analysis of incidence of ischaemic [13] [14] [15] 17, 33, [50] [51] [52] [53] [54] [55] [56] [57] and haemorrhagic [13] [14] [15] 17, 33, 52, 53 stroke by different rheumatic diseases with a general population comparator. 58
Stroke Risk: Pooled Rate Ratios
Sufficient data to perform meta-analysis of rate ratios for stroke incidence among stroke subtypes versus the general population were only available for RA and SLE. In RA versus the general population, the pooled odds of ischemic stroke (3481 strokes; 86 280 patients) and hemorrhagic stroke (562 strokes; 84 419 patients) were 1.64 (95% CI, 1.32-2.05) and 1.68 (1.11-2.53), respectively (Figures 1 and 2) . In SLE versus the general population, the pooled odds of ischemic stroke (945 strokes; 55 699 patients) and hemorrhagic stroke (164 strokes; 44 062 patients) were 2.11 (1.66-2.67) and 1.82 (1.07-3.09), respectively (Figures 1 and 2 ).
Subtypes of Ischemic Stroke
For SLE, 2 studies 17,50 provide incidence rate data for ischemic stroke subtypes: among 490 SLE patients, 17 13 had cortical strokes (equivalent to 271 cortical strokes per 100 000 personyears) and 4 had lacunar strokes (83 per 100,000) from 4802 person-years follow-up; among 232 SLE patients, 50 20 had large artery strokes (1150 per 100 000), 17 had small vessel F1,F2 
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April 2016 strokes (997 per 100 000) and 4 had cardioembolic strokes (230 per 100 000) from 1739 person-years follow-up. There are limited comparative data from the general population but Sacco et al 59 report annual incidence rates for lacunar stroke as 33 per 100 000 population. There were insufficient data to pool rate ratios among ischemic stroke subtypes.
Age, Rheumatic Disease and Stroke
The pooled odds of any stroke (11 879 strokes; 340 548 patie nts) 9,12-17,33,60 across 5 rheumatic diseases (data were available for RA, SLE, psoriasis, ankylosing spondylitis, and gout) versus the general population was 1.38 (95% CI, 1.21-1.57) ( Figure 3 (Figure 3 ). The age categories were significantly different (χ 2 test for subgroups, P=0.007). We include a study by study review of stroke by age categories across stroke in general and by ischemic and hemorrhagic stroke subtypes in Table IV in the online-only Data Supplement. 
Structural MRI Brain Imaging Findings
We reviewed numerous MRI studies of the brain in rheumatic diseases. The details are provided in Table V in the onlineonly Data Supplement. Most were small, many investigated neurologically symptomatic patients only (for example comparing neurolupus with SLE), and few controlled for age and known vascular risk factors.
Discussion
Brain damage from any type of stroke, from ischemic and hemorrhagic stroke, and silent vascular damage such as WMHs is increased in most rheumatic diseases. Most data are for stroke in general, but ischemic and hemorrhagic strokes were also increased in our new pooled analyses of RA and SLE, as were silent vascular disease markers. RA, SLE, AS, gout, and to a lesser degree psoriasis carry a higher risk of stroke over the general population. Stroke incidence varies across rheumatic diseases (Table) and seem higher than the general population (eg, Rothwell et al 58 report annual incidence rates for ischemic and hemorrhagic stroke as 141 (95% CI, 127-156) and 12 (9-17) per 100 000 population, respectively).
Rheumatic disease patients aged <50 have a particularly high stroke risk compared with the general population. There was no additional stroke risk in OA. Other rheumatic diseases are understudied. Although increased stroke risk may reflect impact on lifestyle through the physical effects of rheumatic diseases, the possibility that increased systemic inflammation affects the brain directly is suggested by the higher stroke risk in inflammatory versus noninflammatory arthropathies. A better understanding of stroke in rheumatic disease would help focus clinical practice on prevention of vascular brain damage, including early lifestyle interventions and any vascular prevention role for anti-inflammatory agents, in these patients. This is the first analysis to quantify stroke subtype rates and risk in rheumatic disease including by age. Our results are 
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April 2016 comparable with Holmqvist et al's 61 meta-analysis of stroke in SLE, including that stroke risk is increased in the patients aged <50, but we include other rheumatic diseases. We were limited by the different methods used in the primary studies although we attempted to correct for this by using random effects meta-analysis. Consistency of reporting of stroke rates is a recognised problem and future studies should attempt to standardize their methods. 62 The increase in risk of vascular disease in RA and SLE is perhaps expected, but we also note the almost doubling of stroke in gout (1.71; 1.68-1.75; n=9951 strokes, n=202 033 patients) over the general population perhaps because of the relationship between gout and metabolic syndrome, or to uric acid's independent association with ischemic and hemorrhagic stroke subtypes. 63 The review's strengths include data mostly from large population-based studies although we only included English language publications. We could not adjust for vascular risk factors or treatments, limiting generalizability, and cannot exclude the possibility of study bias. Patients with rheumatic disease are often assiduously monitored (because of the disease and treatments), and so might have minor neurological problems investigated more compared with the general population.
Data on ischemic stroke subtypes were limited to 2 studies in SLE. 17, 50 Many more studies reported on SVD features among patients with several rheumatic diseases. Although small size and disparate reporting precluded meta-analysis, the general impression was of more vascular lesions in rheumatic diseases.
The increased stroke risk at earlier ages uses data from 340 548 patients (11 879 strokes). The excess risk was almost double that of the general population, highest in those <50 years, and declined steadily to approach that of the general population >65. However, there was heterogeneity in study reporting and inconsistencies in age categories (despite guidance to use mid-decade age bands 62 ). The clear trend for higher stroke risk <50 years suggests that atherosclerosis is unlikely to be the sole pathogenic driver. Systemic inflammation may play a role. The increased risk at younger ages might reflect more rheumatic disease activity before the inflammation is well controlled.
The risk of any stroke, ischemic or hemorrhagic stroke, and MRI findings seem worse in inflammatory arthropathies (RA, SLE, AS, gout, psoriatic arthritis) than noninflammatory arthropathies (OA). Inflammation is a risk factor for stroke 64 and plasma markers of inflammation (C-reactive protein, tumor necrosis factor-a, interleukin-6) are associated with stroke 65 and increased WMH burden. Antiphospholipid antibodies increase the risk of thrombus: in RA, strokes (and preclinical brain abnormalities such as WMH) are more common in those with antiphospholipid than those without. [66] [67] [68] Therefore, inflammation generated in the rheumatic diseases may be at least in part responsible for the marked stroke risk and overt brain lesions, and increased risk at younger ages.
A large brain imaging population study with detailed stroke phenotyping is needed to fully characterize stroke subtypes including SVD in rheumatic patients. A clear picture of increased stroke risk in younger patients is established indicating a need to a) unravel the extent to which inflammation, lifestyle, antirheumatic treatments, and risk factors (traditional as well as new) contribute to stroke risk and b) whether aggressive management of these risk factors including inflammation can ameliorate the stroke risk. Imaging features such as WMH might assist in identifying rheumatic disease patients who are at particularly high risk of stroke, as do WMH in the general ageing population. 69 
